CHAPTER 4 DRUGS AND MEDICATIONS

GR401 Determining the Equine Drugs and Medications Designation for Each Breed or Discipline
GR402 Testing
GR403 Cooperation
GR404 Accountability of Trainers and Other Persons Responsible
GR405 Equine Drugs and Medications Testing in Connection with an Appeal Measurement
GR406 Results, Confirmatory Analysis, and Retest
GR407 Management Procedures
GR408 Interpretations of the Federation Equine Drugs and Medications Chapter and its Application to Particular Substances
GR409 Equine Drugs and Medications, Prohibited Substance Provisions
GR410 Equine Drugs and Medications, The Therapeutic Substance Provisions
GR411 Conditions For Therapeutic Administrations of Forbidden Substances
GR412 Administrative Penalties
GR413 Human Drug Testing
GR414 Prohibited Practices
GR401-408. Equine Drugs and Medications Provisions Applicable to All Breeds and/or Disciplines

GR401 Determining the Equine Drugs and Medications Designation for Each Breed or Discipline

1. The Board of Directors shall designate every Breed, Discipline, and/or Group competing under Federation Rules as either a Prohibited Substance Group or a Therapeutic Substance Group, as outlined herein below.

2. At each Annual Meeting, each Division Committee shall determine by a majority vote and shall indicate to the Chief Administrator of the Equine Drugs and Medications Program its preference for its Breed or Discipline to be designated as (or to be part of) either a Prohibited Substance Group or a Therapeutic Substance Group. In any instance where more than one Division Committee is responsible for a Breed and/or Discipline Group, after each committee has determined its preference by a majority vote, unanimity between and/or among the Division Committees of the Group shall be required to invoke a recommendation to be designated a Prohibited Substance Group. Absent such concurrence, the joint recommendation of the Division Committees of the Group shall be construed as a recommendation in favor of designation as a Therapeutic Substance Group.

3. Each Division Committee shall have responsibility to recommend for its division.

4. At its meeting at the Federation’s Annual Meeting, the Equine Drugs and Medications Committee shall take into consideration these recommendations and the written recommendations of the respective Affiliate Associations in this regard, and it shall enact the designation for each Breed, Discipline, and/or Group. The effective dates of these designations shall coincide with the effective dates of the newly published Rule Book.

5. These designations shall be reviewed by each Division Committee at the subsequent Rule Change Convention.

6. Every horse and/or pony competing at Federation competitions and/or events shall be subject to either the Prohibited Substance Provisions (GR409) or the Therapeutic Substance Provisions (GR410-412), depending upon its Breed’s, Discipline’s, and/or Group’s designation, and it shall be required to compete in compliance therewith, whether competing in unrated or rated classes and/or divisions.

7. Any horse and/or pony that competes in more than one Breed, Discipline, and/or Group at a competition, one of which is a Prohibited Substance Group, shall be required to be in compliance with the Prohibited Substance Provisions at all times while competing in any and/or all classes and/or divisions at that competition.

GR402 Testing

1. Horses and/or ponies competing at a Licensed Competition are subject to examination by a licensed veterinarian who must be appointed by the Administrator of the Equine Drugs and Medications Program. Said appointed veterinarian, with the approval of the Administrator, may appoint a technician to perform certain duties under this Rule. The examination may include physical, urine, blood tests and/or any other test or procedure at the discretion of said veterinarian necessary to effectuate the purposes of this rule. Said veterinarian may examine any or all horses and/or ponies in a class or all classes in a competition or any horses and/or ponies entered in any class, whether in competition or not, if on the competition grounds, or any horse and/or pony withdrawn by any exhibitor within 24 hours prior to a class for which it has been entered.

2. Whether a horse and/or pony is in competition or not, refusal to submit the horse and/or pony for examination or to cooperate with the veterinarian or his agents constitutes a violation and subjects the responsible person to penalties under GR406.

3. Trainers who are not able to accompany Federation drug testing personnel and the horse and/or pony to the location where sample collection is to take place, to act as witness to the collection and sealing of blood and urine
samples, and to sign the drug collection documents in the appropriate places as witness, must appoint an agent to do so. The absence of such a witness shall constitute a waiver of any objection to the identification of the horse and/or pony tested and the manner of collection and sealing of the samples.

4. Upon the collection of a sufficient number of tubes of blood from the horse or pony, the tubes shall be divided into two groups. One group shall be labeled and identified as Blood Sample A and the other as Blood Sample B, and they shall be sealed accordingly. Upon the collection of a sufficient volume of urine from the horse or pony, a portion of the sample shall be poured into a second urine sample container. One container shall be labeled and identified as Urine Sample A and the other as Urine Sample B, and they shall be sealed accordingly. These procedures shall be performed whether or not the trainer or his/her appointed witness is present as provided for in Section 3 above.

5. In the event reasonable attempts at sample collections from the horse or pony do not provide a sufficient number of tubes of blood or a sufficient volume of urine to be divided, labeled, and identified as Samples A and B, as determined by the testing veterinarian and/or technician, the sample(s) obtained (if obtained) shall be labeled and identified as Sample(s) A only, and it shall be recorded in the records of the Equine Drugs and Medications Program that the corresponding Sample(s) B does (do) not exist, in which event the obtained Sample(s) shall be subject to testing.

6. A blood sample may be retested under these Rules at any time exclusively at the direction of the Federation. The retesting of a sample may lead to a violation only if the sample was retested within three (3) years from the sample collection date. In order to constitute a violation under these rules, the substance detected in the retested sample must (i) have been forbidden at the time of sample collection; and (ii) not a therapeutic substance, which for purposes of this rule includes only the Controlled Medications on the FEI Prohibited Substances List (available at http://www.fei.org/fei/cleansport) in effect on the sample collection date.

7. In the event that the retested sample proves positive, and the retest was conducted more than one (1) year since the date of collection, no prizes or awards will be required to be returned.

**GR403 Cooperation**

1. Cooperation with the veterinarian and/or his agent(s) includes:
   a. Taking the horse and/or pony and the veterinarian and/or his agent(s) immediately to the location selected by said veterinarian and/or agent(s) for testing the horse and/or pony and presenting it for testing.
   b. Assisting the veterinarian and/or his agent(s) in procuring the sample promptly, including but not limited to removing equipment from the horse and/or pony, leaving it quietly in the stall and avoiding any distractions to it. Schooling, lengthy cooling out, bandaging and other delays of this type shall be construed as noncooperation.
   c. Polite attitude and actions toward the veterinarian and/or his agent(s).

**GR404 Accountability of Trainers and Other Persons Responsible**

1. Trainers and other Persons Responsible, in the absence of substantial evidence to the contrary, are responsible and accountable under the penalty provisions of these rules. The trainer and other Persons Responsible are not relieved from such responsibility as a result of the lack or insufficiency of stable security.

2. The Persons Responsible may include the individual who rides, vaults, or drives the horse and/or pony during a competition; the Owner; and/or Support Personnel.

3. Support Personnel is defined to include but is not limited to grooms, handlers, longeurs, and veterinarians may be regarded as additional Persons Responsible if they are present at the competition or have made a relevant decision about the horse and/or pony.

4. A trainer is defined as any adult or adults who has or shares the responsibility for the care, training, custody, condition, or performance of a horse and/or pony. Said person must sign the entry blank of any Licensed Competition
whether said person be a trainer, owner, rider, agent and/or coach. Where a minor exhibitor has no trainer, then a parent, guardian or agent or representative thereof must sign the entry blank and assume responsibility as trainer. The name of the trainer must be designated as such on the entry blank. It is the responsibility of trainers as well as competition management to see that entry blanks contain all of the required information. The responsibilities of a trainer include, but are not limited to the following:

a. for the condition of a horse or pony at a Licensed Competition (whether or not they have signed an entry blank),
b. to guard each horse and/or pony at, and sufficiently prior to, a Licensed Competition such as to prevent the administration by anyone of, or its exposure to, any forbidden substance, and
c. to know all of the provisions of this Chapter 4 (including any advisories or interpretations published in equestrian) and all other rules and regulations of the Federation and the penalty provisions of said rules. For purposes of this rule, substantial evidence means affirmative evidence of such a clear and definite nature as to establish that said trainer, or any employee or agent of the trainer, was, in fact, not responsible or accountable for the condition of the horse and/or pony. If any trainer is prevented from performing his or her duties, including responsibility for the condition of the horses and/or ponies in his or her care, by illness or other cause, or is absent from any Licensed Competition where horses and/or ponies under his or her care are entered and stabled, he or she must immediately notify the competition secretary and, at the same time, a substitute must be appointed by the trainer and such substitute must place his or her name on the entry blank forthwith. Such substitution does not relieve the regular trainer of his/her responsibility and accountability under this rule; however, the substitute trainer is equally responsible and accountable for the condition of such horses and/or ponies.

5. The trainer and owner acknowledge that the trainer represents the owner regarding horses and/or ponies being trained or managed, entries, scratches for any reason and any act performed on any horse and/or pony under the care and custody of the trainer.

6. In the case of a horse and/or pony competing under the Therapeutic Substance Provisions, any trainer and/or Persons Responsible subject to these rules who actually administers, attempts to administer, instructs, aids, conspires with another to administer or employs anyone who administers or attempts to administer a forbidden substance to a horse and/or pony which might affect the performance of said horse and/or pony at a competition licensed by the Federation without complying with GR411, is subject to the penalties provided in GR406.

7. Any trainer and/or Persons Responsible subject to these rules who administers, attempts to administer, instructs, aids, conspires with another to administer or employs anyone who administers or attempts to administer any substance to a horse and/or pony by injection or by any other route of administration, whether the substance is forbidden or permitted, in the competition ring of a competition licensed by the Federation during a scheduled class, is subject to the penalties provided in GR406.

GR405 Equine Drugs and Medications Testing in Connection with an Appeal Measurement

1. Each animal submitted for an appeal measurement is subject to the Drugs and Medications Chapter at the time of said measurement and/or concurrent examinations, and said animal must be in compliance therewith.

2. Each animal submitted for an appeal measurement must have drug testing samples collected at the time of said measurement and/or concurrent examinations. No sample is a drug testing sample unless it is collected by and/or under the direct supervision of Federation drug testing personnel, who must be appointed by the Administrator of the Equine Drugs and Medications Program to collect samples from the animal in question in connection with said measurement.

3. Each animal submitted for an appeal measurement must have both a urine sample and a blood sample collected at the time of said measurement and/or concurrent examinations. Both the urine sample and the blood sample must be of sufficient volume for drug testing purposes, as determined by the Administrator of the Equine Drugs and Medications Program. Said sample collections shall be conducted in accordance with procedures which are the sole
prerogative of the Federation drug testing personnel. As deemed necessary by the Federation testing veterinarian, the animal shall be administered furosemide to cause it to produce a urine sample in a timely manner.

4. Every blood sample and/or urine sample collected in connection with an appeal measurement and all portions thereof are the sole property of the Federation. Said samples and all portions thereof must remain in the sole custody of the Federation drug testing personnel at all times during said measurement and/or concurrent examinations, and subsequently they must be submitted to the Federation’s laboratory for testing in accordance with the instructions of the Administrator of the Equine Drugs and Medications Program.

5. The entire cost of sample collections and testing conducted in connection with an appeal measurement, including the fees and expenses of Federation drug testing personnel, shipping costs for equipment and samples, laboratory charges, etc., as determined by the Administrator of the Equine Drugs and Medications Program, must be paid in full by the appellant within 30 days of the submission of an invoice, regardless of the outcome of said measurement, and regardless of the laboratory results. A deposit in cash or certified check equal to the costs of sampling and testing, as estimated by the Administrator of the Equine Drugs and Medications Program, may be required prior to the measurement.

6. No appeal measurement is valid absent written affirmation of the CEO or his designee confirming the receipt of negative drug testing results from the Federation’s laboratory, indicating that both the urine and blood sample collected from the animal in question in connection with said measurement and/or concurrent examinations were found to contain no forbidden substance, said results having been issued to the Administrator of the Equine Drugs and Medications Program. Any instance involving a finding of forbidden substance shall additionally result in the issuance of a charge of violation of Chapter 4 for adjudication by the Hearing Committee in accordance with the provisions of Chapters 6 and 7.

**GR406 Results, Confirmatory Analysis, and Retest**

1. Blood and urine samples labeled and identified as Samples A shall be subjected to chemical analysis by the Federation Drug Testing Laboratory or by a laboratory with which the Federation has contracted for its services. Blood and urine samples labeled and identified as Samples B shall be stored securely, unopened, at the Federation Drug Testing Laboratory, to be used in the event of a confirmatory analysis, or in the event of a future analysis.

2. In the event the chemical analysis of Blood or Urine Sample A is negative, i.e., no forbidden substance or any metabolite or analogue thereof is found to be present in the sample, the corresponding Blood or Urine Sample B may be frozen and maintained, at the Federation Equine Drug Testing and Research Laboratory, for possible future chemical analysis.

3. In the event the chemical analysis of Blood or Urine Sample A is positive, i.e., a forbidden substance or any metabolite or analogue thereof is found to be present in the sample, this shall be prima facie evidence that the forbidden substance was administered in some manner to said horse or pony, whether intentionally or unintentionally, or otherwise was caused to be present in the tissues, body fluids or excreta of the horse or pony at the competition, whether intentionally or unintentionally, such that the trainer(s) deemed responsible and accountable for its condition is (are) liable under the provisions of GR404.

4. In the event the chemical analysis of Blood or Urine Sample A is positive, the Federation shall notify the Trainer, Persons Responsible (if applicable), and the Owner of the Horse of their right to promptly request the analysis of the B sample, or, failing such request, that the B sample analysis is deemed waived. The Trainer, Persons Responsible (if applicable), and the Owner of the Horse are deemed to have waived their right to a B Sample analysis if they do not submit the Confirmatory Analysis Request Form within the 15 business days. Within seven (7) days of receipt of the duly executed Confirmatory Analysis Request Form (B Sample), the Federation shall coordinate such analysis. The Trainer, Persons Responsible (if applicable), and Owner of the Horse may accept the A Sample
analytical results by waiving the right to a B sample analysis.

5. The confirmatory analysis of the corresponding Blood or Urine Sample B shall be performed by a drug testing laboratory that is approved by the Federation and agreed upon by the person charged who requests the confirmatory analysis, which laboratory must have demonstrated proficiency in performing the necessary confirmatory analysis, provided the corresponding Blood or Urine Sample B exists and is of sufficient volume to permit a confirmatory analysis. In the event the drug testing laboratory that analyzed Sample A is the only laboratory that has demonstrated proficiency in performing the necessary confirmatory analysis, this laboratory shall be the only laboratory to perform the confirmatory analysis of the corresponding Sample B. Upon the completion of the confirmatory analysis, the laboratory performing the confirmatory analysis shall forward its findings and supporting data to all parties.

6. In the event no agreement is reached as to a laboratory as required in section 5 above, and the person charged who requests the confirmatory analysis does not revoke his/her request, the confirmatory analysis of the corresponding Blood or Urine Sample B shall be performed by the Federation Drug Testing Laboratory, or by a laboratory with which the Federation has contracted for its services, and shall forward its findings and supporting data to all parties. Both the results of the analysis of Sample A (and supporting data) and the results of the confirmatory analysis of the corresponding Sample B, if any (and supporting data, if any), shall be admissible as evidence in any hearing or proceeding pertaining to this matter.

7. In the event the corresponding Blood or Urine Sample B does not exist, or is of insufficient volume to permit a confirmatory analysis, and there exists a remaining aliquot of Blood or Urine Sample A which is of sufficient volume to permit a retest, as determined by the Federation, a person charged who requests the retest of Blood or Urine Sample A must make the request in writing to the Federation and it must be received within 7 days of the determination that the corresponding Blood or Urine Sample B does not exist or is of insufficient volume to permit a confirmatory analysis.

8. Any requested re-test of the remaining aliquot of Blood or Urine Sample A, provided it is of sufficient volume to permit a retest, shall be performed by the Federation Drug Testing Laboratory, or by a laboratory with which The Federation has contracted for its services.

9. The retest of the remaining aliquot of Blood or Urine Sample A may be witnessed by a Witnessing Analyst appointed by the person charged who requests such analysis at the same time as the retest is requested. The Witnessing Analyst must be a qualified analytical chemist employed by an equine drug testing laboratory. If no Witnessing Analyst is appointed by the person requesting the retest, or if the Witnessing Analyst is unavailable within a reasonable time, the requested retest of the remaining aliquot of Blood or Urine Sample A shall proceed without the Witnessing Analyst.

10. In the event the Witnessing Analyst appointed by the person requesting the retest of the remaining aliquot of Blood or Urine Sample A is satisfied that the positive result is correct, the Federation must be informed immediately by fax with confirmation by letter.

11. In the event the Witnessing Analyst is not satisfied that the result of the retest of the remaining aliquot of Blood or Urine Sample A is correct, the Federation must be informed immediately by fax followed by a written report setting forth the basis for the Witnessing Analyst’s opinion. Copies of the original and subsequent results and supporting analytical data must be submitted to the Federation Hearing Committee as part of the hearing record in the case, for resolution by it of any and all issues regarding the original analysis of Blood or Urine Sample A and the retest of the remaining aliquot of Blood or Urine Sample A.

12. By requesting the confirmatory analysis of the corresponding Blood or Urine Sample B, or the retest of the remaining aliquot of Blood or Urine Sample A, or by requesting that the retest be witnessed by a Witnessing Analyst, the person charged who makes such request(s) agrees to and must pay any and all fees, costs and expenses relating to the confirmatory analysis or the retest, whether it is performed by a mutually agreed upon laboratory, by the Federation Drug Testing Laboratory, or by a laboratory with which The Federation has contracted for its services, upon
the presentation an invoice by the Federation, and any and all fees, costs, and expenses relating to the Witnessing Analyst.

13. After chemical analysis of the B sample, if the laboratory’s confirmatory analysis:
   a. Does not substantially confirm the Federation Equine Drug Testing and Research Laboratory’s findings, then any allegations that the substance in question was present at the time that the samples were collected shall be dismissed; or
   b. Substantially confirms the Federation Equine Drug Testing and Research Laboratory’s findings, the finding shall be considered conclusive.

14. In the case of a horse and/or pony competing under the Therapeutic Substance Provisions, if the chemical analysis of the sample taken from such horse and/or pony indicates the presence of a forbidden substance or any metabolite or analogue thereof and all the requirements of GR411 have been fully complied with, the information contained in said Equine Drugs and Medications Report Form and any other relevant evidence will be considered by the Federation in determining whether a rule violation was committed by any person(s) responsible or accountable for the condition of the horse and/or pony under the provisions of this rule.

15. When a positive report is received from the chemist identifying a forbidden substance, or any metabolite or analogue thereof, a hearing will be held in accordance with Chapter 6, except as may otherwise be provided by GR412. No trainer, responsible or accountable for the condition of said horse and/or pony, will be suspended, or a horse and/or pony barred from competition, until after an administrative penalty has been assessed or after the conclusion of a hearing and a written ruling thereon has been made.

16. The owner or owners of a horse and/or pony found to contain a forbidden substance or any metabolite or analogue thereof may be required to forfeit all prize money, sweepstakes, added money and any trophies, ribbons and “points” won at said competition by said horse and/or pony and the same will be redistributed accordingly. The owner must pay a fee of $300 to said competition. Points accumulated toward Horse of the Year Awards prior to said competition may be nullified and redistributed at the discretion of the Hearing Committee. If, prior to or at a hearing, the Federation as the charging party, determines that one or more persons, not previously charged as a trainer should also be charged as a trainer, then, upon application by the Federation, the Hearing Committee may, in its discretion, continue or adjourn the hearing, in whole or in part, to permit a new or amended charge to be issued (unless the person(s) to be charged waive notice).

17. A trainer of a horse and/or pony found to contain such forbidden substance or any metabolite or analogue thereof is subject to whatever penalty is assessed by the Hearing Committee, except for administrative penalties issued by the Chairman of the Equine Drugs and Medications Committee and accepted, as provided by GR412. Said trainer may be fined and may be suspended from all participation in Licensed Competitions for a period of one year for the first offense, and for a longer period for a second or later offense, said suspension to be served at any time at the discretion of the Hearing Committee.

The horse and/or pony may be suspended for any period of time specified by the Hearing Committee. In determining an appropriate penalty under these rules, the Hearing Committee may take into account such factors and circumstances as it may deem relevant, including but not limited to
   a. the pharmacology of the forbidden substance,
   b. the credibility and good faith of the person charged or of other witnesses,
   c. penalties determined in similar cases, and
   d. past violations of any Federation rules (or the lack thereof).
   e. reliance upon the professional ability or advice of a veterinarian who is a licensed graduate of an accredited veterinary school and who is in good standing in the state in which he/she primarily practices.

18. If the Hearing Committee determines that any violation or attempted violation of this Rule was willful and/or intentional, there shall not be any limit to the period of a suspension, and the Hearing Committee may impose other and
GR4 - DRUGS AND MEDICATIONS

significantly greater penalties than it would have in the absence of such a determination.

19. A blood sample may be retested under these Rules at any time exclusively at the direction of the Federation. The retesting of a sample may lead to a violation only if the sample was retested within three (3) years from the sample collection date. In order to constitute a violation under these rules, the substance detected in the retested sample must (i) have been forbidden at the time of sample collection; and (ii) not a therapeutic substance, which for purposes of this rule includes only the Controlled Medications on the FEI Prohibited Substances List (available at http://www.fei.org/fei/cleansport) in effect on the sample collection date.

20. In the event that the retested sample proves positive, and the retest was conducted more than one (1) year since the date of collection, no prizes or awards will be required to be returned.

GR407 Management Procedures

1. To provide funds for research, inspection and enforcement of rules regarding use of medications and drugs, each Licensed Competition, except where prohibited by law, must assess the exhibitors a fee of $8 for each horse and/or pony entered in the competition, except the fee shall be $25 for each horse entered in an FEI sanctioned competition. Participants in the following classes are exempted from payment:
   a. leadline
   b. exhibitions
   c. games and races,
   d. classes for 4-H members,
   e. Recognized Academy classes at Dressage competitions. BOD 12/12/16 Effective 1/1/17
   f. Opportunity classes
   g. Classes at Regular or Local Competitions restricted to breeds or disciplines whose rules are not included in the USEF rulebook.
   h. However, these classes are not exempt from the Drugs and Medications Chapter itself. Within 10 days after a competition, competition management must forward to the Federation a sum representing the above fee times the number of horses and/or ponies entered in the nonexempt classes of the competition plus the number of horses and/or ponies scratched where the fee is not refunded, such sum to be held by the Federation in a separate fund for use to accomplish the purpose set forth above. BOD 11/7/16 Effective 12/1/16

2. It is a violation for a Licensee to assess and/or collect a drug enforcement fee in excess of or in addition to that specified and required by GR407.1 of these rules, unless said assessment is approved in writing by the Federation in advance, and then only under the terms and conditions set forth.

3. It is a violation for a Licensee to withhold from the Federation any or all of the drug fees collected in accordance with GR407.1, for any purpose, including to defray the expenses incurred providing stalls, passes, and other items to the Federation drug testing personnel, as required by GR407.4 and .5.

4. Each Licensed Competition shall, at its own cost and expense, set aside and make available to The Federation testing personnel upon request suitable facilities conveniently located for the veterinarian appointed by the Federation and his or her technicians to collect equine blood and urine samples. Suitable facilities means one or more stalls if available, as requested, that are well lit, clean, dry, freshly bedded, and having a door or gate that can be secured.

5. Each Licensed Competition, upon request, must furnish the veterinarian appointed by The Federation and/or the Administrator of the Equine Drugs and Medications Program by mail forthwith, with the requested number of official passes and parking passes for the veterinarians and technicians to have immediate and free access to all areas at said Licensed Competition.

6. Competition management must cooperate with and exhibit polite attitude and actions toward the veterinarian and/or
GR408 Interpretations of the Federation Equine Drugs and Medications Chapter and its Application to Particular Substances

Any questions regarding the interpretation of this Chapter, including the application of this Chapter to particular substances, should be directed to the office of the Federation Equine Drugs and Medications Program, 956 King Avenue, Columbus, Ohio 43212-2655. (800) 633-2472, (614) 299-7707, FAX (614) 299-7706. Trainers and/or owners who seek advice concerning the interpretation and application of this rule should not rely solely upon interpretations or advice by private or competition veterinarians, competition officials, competition personnel, or other persons, but should also obtain verification of any such interpretations or advice from the Federation Equine Drugs and Medications Program office. Any trainer or owner who is uncertain about whether this rule applies in any given situation would be well advised to withdraw the affected horse and/or pony from competition until such time as the Federation Equine Drugs and Medications Program office has been consulted.

GR409 Equine Drugs and Medications, Prohibited Substance Provisions

1. This paragraph applies only to FEI Banned Substances and Methods.

For all Federation Equestre Internationale (FEI) recognized disciplines, Articles 2 (what constitutes a violation), 3 [proof of violations (except 3.1 and 3.2.3)], 4 (banned substances and methods), and 8.2 (principles of fair hearing) of the FEI Equine Anti-Doping rules govern. Those Articles are incorporated by reference as if fully set out herein and can be found at www.fei.org or the Drugs & Medications tab at www.usef.org. For purposes of this rule, the designation of “Person Responsible” in the incorporated provisions of the FEI Equine Anti-Doping rules shall refer to the individual(s) found to be the trainer of the horse as defined by GR404.

2. No horse and/or pony competing in a Breed or Discipline designated as (or part of) a No Prohibited Substance Group is to be shown in any class at a competition licensed by the Federation if it has been administered in any manner or otherwise contained in its tissues, body fluids or excreta a prohibited substance as defined in the FEI Equine Anti-Doping and Controlled Medication Regulations, which can be found at www.fei.org.

3. EXHIBITORS, OWNERS, TRAINERS, AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, AND PRODUCTS OF ANY KIND, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM NO DOUBT CONTAIN ONE OR MORE FORBIDDEN SUBSTANCES.

GR410 Equine Drugs and Medications, The Therapeutic Substance Provisions

1. No horse and/or pony competing in a Breed or Discipline designated as (or part of) a Therapeutic Substance Group is to be shown in any class at a competition licensed by the Federation (see also GR402.1, last sentence) if it has been administered in any manner or otherwise contains in its tissues, body fluids or excreta a forbidden substance except as provided in GR411. Any horse and/or pony that competes in more than one Breed, Discipline, and/or Group at a competition, one of which is a Prohibited Substance Group, shall be required to be in compliance with the Prohibited Substance Provisions at all times while competing in any and/or all classes and/or divisions at that competition. For purposes of this rule, a forbidden substance is:

   a. Any stimulant, depressant, tranquilizer, local anesthetic, psychotropic (mood and/or behavior altering) substance, or drug which might affect the performance of a horse and/or pony (stimulants and/or depressants are defined as substances which stimulate or depress the cardiovascular, respiratory or central nervous systems), or any metabolite and/or analogue of any such substance or drug, except as expressly permitted by this rule.

   b. Any corticosteroid present in the plasma of the horse/pony other than dexamethasone (see GR410.5b).

   c. Any nonsteroidal anti-inflammatory drug in excess of one present in the plasma or urine of the horse/pony
d. Any substance (or metabolite and/or analogue thereof) permitted by this rule in excess of the maximum limit or other restrictions prescribed herein.
e. Any substance (or metabolite and/or analogue thereof), regardless of how harmless or innocuous it might be, which might interfere with the detection of any of the substances defined in (a), (b), (c) or (e) or quantification of substances permitted by this rule.
f. Any anabolic steroid (GR411 below does not apply).

2. EXHIBITORS, OWNERS, TRAINERS, AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, AND PRODUCTS OF ANY KIND, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM MAY CONTAIN A FORBIDDEN SUBSTANCE.

3. The full use of modern therapeutic measures for the improvement and protection of the health of the horse and/or pony is permitted unless:
a. The substance administered is a stimulant, depressant, tranquilizer, local anesthetic, drug or drug metabolite which might affect the performance of a horse and/or pony or might interfere with the detection of forbidden substances or quantification of permitted substances; or
b. More than one nonsteroidal anti-inflammatory drugs are present in the plasma or urine of the horse/pony (GR411 does not apply); exception: salicylic acid; or
c. The presence of such substance in the blood or urine sample exceeds the maximum limit or other restrictions prescribed herein below.

4. Restrictions concerning the nonsteroidal anti-inflammatory drugs are as follows:
a. The maximum permitted plasma concentration of diclofenac is 0.005 micrograms per milliliter.
b. The maximum permitted plasma concentration of phenylbutazone is 15.0 micrograms per milliliter.
c. The maximum permitted plasma concentration of flunixin is 1.0 micrograms per milliliter.
d. The maximum permitted plasma concentration of ketoprofen is 40.0 nanograms per milliliter.
e. The maximum permitted plasma concentration of meclofenamic acid is 2.5 micrograms per milliliter.
f. The maximum permitted plasma concentration of naproxen is 40.0 micrograms per milliliter.
g. Not more than one of the substances listed in (a) through (g) are permitted to be present in the same plasma or urine sample (GR411 does not apply).
h. The maximum permitted plasma concentration of firocoxib is 0.240 micrograms per milliliter.
i. Any nonsteroidal anti-inflammatory drug not listed in (a) through (g) above is forbidden to be present in the plasma or urine sample (GR411 does not apply); exception: salicylic acid.
j. Any nonsteroidal anti-inflammatory drug that becomes approved for use in horses can be added to the list of those permitted, after the completion, review and approval of the needed research.

5. Restrictions concerning other therapeutic substances are as follows:
a. The maximum permissible plasma concentration of methocarbamol is 0.5 micrograms per milliliter.
b. The maximum permitted plasma concentration of dexamethasone is 0.5 nanograms per milliliter.

6. Thresholds for substances of possible dietary origin are as follows:
a. The maximum permissible urine concentration of theobromine is 2.0 micrograms per milliliter.

7. Additional restrictions concerning particular classes and/or divisions (GR411 does not apply):
a. In the breeding/in-hand classes for three-year-olds and under in the Arabian, Half Arabian, and Anglo Arabian Division, any anabolic steroid is forbidden. (See HOW LONG DRUGS REMAIN DETECTABLE in the current Drugs and Medications Rules Pamphlet for guidelines).

GR411 Conditions For Therapeutic Administrations of Forbidden Substances
1. A horse and/or pony exhibiting at a Licensed Competition pursuant to the Therapeutic Substance Provisions that receives any medication which contains a forbidden substance is not eligible for competition unless all of the following requirements have been met and the facts are furnished in writing on a timely-submitted official Equine Drugs and Medications Report Form:

a. The medication must be therapeutic and necessary for the diagnosis or treatment of an existing illness or injury. Administration of a forbidden substance for non-therapeutic or optional purposes (such as, by way of example only, shipping, clipping, training, turning out, routine floating or cleaning of teeth, non-diagnostic nerve blocking, uncasting, mane pulling or non-emergency shoeing) is not considered to be therapeutic. Any trainer who is uncertain about whether a particular purpose is considered to be therapeutic would be well advised to consult the Federation Equine Drugs and Medications Program office.

b. The horse and/or pony must be withdrawn from competition for a period of not less than 24 hours after the medication is administered.

c. The medication must be administered by a licensed veterinarian, or, if a veterinarian is unavailable, only by the trainer pursuant to the advice and direction of a veterinarian.

d. Identification of medication—the amount, strength and mode of administration.

e. Date and time of administration.

f. Identification of horse and/or pony, its name, age, sex, color and entry number.

g. Diagnosis and reason for administration.

h. Statement signed by person administering medication.

i. Equine Drugs and Medications Report Form filed with the Steward/Technical Delegate or Designated Competition Office Representative within one hour after administration or one hour after the Steward/Technical Delegate or Designated Competition Office Representative returns to duty if administration is at a time other than during competition hours.

j. The Steward, Technical Delegate, or Designated Competition Office Representative must sign and record the time of receipt on the Equine Drugs and Medications Report Form.

k. At selection trials for World Championships, and/or Olympic and/or Pan American Games, the requirement of subsection (b) above, that the horse or pony must be withdrawn from competition for a period of not less than 24 hours after the medication is administered will not apply, provided that:

1. the competition is conducted pursuant to the written selection procedures as approved by the Federation Board of Directors;

2. the written selection procedures specifically allow for therapeutic administrations of medications by a USEF-appointed veterinary panel within 24 hours preceding competition, and the written selection procedures are in no case less stringent in this regard than the FEI Veterinary Regulations (Articles 1006.7 and 1006.8) and guidelines pursuant thereto;

3. all requirements of the written selection procedures regarding therapeutic administrations of medications have been met;

4. all requirements of this Rule have been met except subsection GR411.1(b); and all persons competing in the competition are eligible and competing for selection.

2. Where all the requirements of GR411 have been fully complied with, the information contained in said Equine Drugs and Medications Report Form and any other relevant evidence will be considered by the Federation in determining whether a rule violation was committed by any person(s) responsible or accountable for the condition of the horse and/or pony under the provisions of this rule.

NOTE: The official Equine Drugs and Medications Report Form is available from the officiating Steward/Technical Delegate and/or Competition Secretary. All required information must be included when filing a report. Failure to satisfy and follow all the requirements of this Rule and to supply all of the information required by such Equine
Drugs and Medications Report Form is a violation of the rules. The Steward/Technical Delegate must report any known violations of this Rule to the Federation for such further action as may be deemed appropriate.

3. Flunixin, in addition to one other substance listed in GR410 (a) through (g), may be found in the same plasma and/or urine sample of a horse under the following conditions and for the treatment of colic or an ophthalmic emergency only: (i) must comply with GR411.1; (ii) the flunixin must have been administered by a veterinarian; (iii) the required medication report form must be signed by the administering veterinarian; and (iv) the horse must be withdrawn from competition for 24 hours following the administration.

GR412 Administrative Penalties

1. The provisions for administrative penalties shall apply to any potential or alleged violation of the Equine Drugs and Medications Rule. The Federation shall hold in abeyance the issuance of charges of rule violation pending further determination by the Chairman of the Equine Drugs and Medications Committee, who shall take into consideration all pertinent information available, including the seriousness of the alleged violation(s), precedents in similar Federation drug cases, and any prior rule violation(s) by the individual(s). At all times while consideration is given as to a determination by the Chairman of the Equine Drugs and Medications Committee, the identity of the horse, rider, trainer, coach, and owner must not be known or disclosed to him.

2. The Chairman of the Equine Drugs and Medications Committee shall, upon consultation with staff, and within 60 days of receipt of laboratory results, make a determination in his or her discretion whether to recommend the issuance of charges by the Federation, whether to recommend a plea agreement, whether to impose administrative penalties, or whether to take no further action in the matter, and shall communicate that decision in writing to the Federation’s CEO or his designee.

3. In the event the Chairman of the Equine Drugs and Medications Committee determines to impose administrative penalties in accordance with GR412.2, in lieu of a recommendation to issue charges, he or she shall be authorized to impose any or all of the penalties enumerated in Chapter 7, GR703, setting forth the terms and conditions for compliance. The trainer(s) and owner(s) shall after receiving written notice of the right to a hearing, after their written waiver of same, and written acceptance of an administrative penalty, be subject to any and all administrative penalties imposed by the Chairman of the Equine Drugs and Medications Committee.

4. The Federation shall give written notification to trainer(s) and owner(s) of administrative penalties determined pursuant to GR412.3 above, the terms and conditions of which shall not be subject to negotiation. An administrative penalty must be approved by the Hearing Committee Co-Chairs before it is offered to the Respondent(s). Once accepted by all parties and by the Hearing Committee, an administrative penalty shall have the same force and effect as would a finding of rule violation by the Hearing Committee following a hearing pursuant to Chapters 6 and 7, and will be published on the Federation’s web site.

5. Any trainer(s), or owner(s), or both, who have received notice of an administrative penalty under GR412.4 and who have not accepted same in writing shall receive a hearing before the Hearing Committee, in accordance with Chapters 6 and 7. Administrative penalties accepted in accordance with this Rule shall be effective immediately, shall be final, and shall not be subject to further review under any circumstance(s).

6. In the event an administrative penalty is not accepted in writing, the Federation shall issue a written charge or charges pursuant to Chapter 6, and the Hearing Committee shall conduct a hearing pursuant to Chapters 6 and 7 upon said charge(s). In the event of a finding of a violation, the Hearing Committee shall not be limited in choice of penalties to those that might have been imposed in accordance with GR412.2 and .3, nor in any such instance shall the Hearing Committee be limited in any other way in exercising all of its prerogatives as set forth in the Bylaws and Rules.

7. A blood sample may be retested under these Rules at any time exclusively at the direction of the Federation. The retesting of a sample may lead to a violation only if the sample was retested within three (3) years from the sample
collection date. In order to constitute a violation under these rules, the substance detected in the retested sample must (i) have been forbidden at the time of sample collection; and (ii) not a therapeutic substance, which for purposes of this rule includes only the Controlled Medications on the FEI Prohibited Substances List (available at http://www.fei.org/fei/cleansport) in effect on the sample collection date.

8. In the event that the retested sample proves positive, and the retest was conducted more than one (1) year since the date of collection, no prizes or awards will be required to be returned.

**GR413 Human Drug Testing**

1. In accordance with the rules of the FEI and of the World Anti-Doping Agency (WADA), any Federation member shall comply with in-competition, no advance notice (NAN), and other out-of-competition drug testing conducted by the FEI, WADA, US Anti-Doping Agency (USADA) or by a WADA-authorized organization or USADA-authorized organization at any time without advanced notice. Failure to cooperate with such in-competition, NAN or other out-of-competition drug testing shall be a violation of Federation rules.

2. In conjunction with the above-described NAN or other out-of-competition drug testing, the Federation is required to submit the names, current addresses, telephone numbers, training times and training and competition locations for individuals and teams as requested by the FEI, WADA, or USADA to enable FEI, WADA, or USADA to conduct NAN or other out-of-competition drug testing. Notwithstanding the foregoing, compliance with anti-doping regulations rests with the individual subject to testing.

3. A finding of violation of human drug rules by USADA or WADA shall be deemed a violation of Federation rules, and the reciprocity provisions of GR615.2 shall be applied.

**GR 414 Prohibited Practices**

1. No injectable substances may be administered to any horse or pony within 12 hours prior to competing, with the following three exceptions subject to paragraph 2 below:
   a. Therapeutic fluids, which amount must consist of a minimum of 1L of polyionic fluids per 100lb of body weight; and which must be used in accordance with the manufacturer’s recommendations and guidelines. The fluids must not be supplemented with concentrated electrolytes, such as magnesium.
   b. Antibiotics. Procaine penicillin G is prohibited under this exception.
   c. Dexamethasone. This is permitted only for the treatment of acute urticaria – (hives). The dose must not exceed 0.5 mg per 100 lb (5.0 mg for 1000 lb horse) if administered more than 6 hours and less than 12 hours prior to entering the competition ring, and must not exceed 1.0 mg per 100 lb (10.0 mg for 1000lb horse) within any 24 hour period.

2. The above exceptions are permitted only when (i) the substance is administered by a licensed veterinarian and no less than 6 hours prior to competing; and (ii) the “Trainer” as defined under General Rule 404 properly files, or causes to be properly filed, an Equine Drugs and Medications Report Form with the Steward/Technical Delegate or competition office representative within one hour after the administration of the substance or one hour after the Steward/Technical Delegate or competition office representative returns to duty if the administration occurs at a time outside competition hours. The Steward/Technical Delegate or competition office representative shall sign and record the time of receipt on the Equine Drugs and Medications Report Form.

3. No horse may be injected with any substance, forbidden or permitted, into an intra-synovial space (joint, tendon sheath, or bursa) within the 4 days preceding competition. No horse less than two years of age may be treated with intrasynovial injections within the 30 days preceding competition.

4. Shockwave Therapy may only be administered by or on the order of a licensed veterinarian. If sedation is required for Shockwave Therapy, only sedation performed by a licensed veterinarian and administered at the same time as the Shockwave Therapy will be considered therapeutic and GR411 will apply. No sedation associated with
GR4 - DRUGS AND MEDICATIONS

Shockwave Therapy will be considered therapeutic if administered within 24 hours prior to competition. No horse may be treated with Shockwave Therapy within the 3 days preceding competition with the following exception:

a. Shockwave Therapy may be administered by a licensed veterinarian within the 3 day prohibited period, but no closer than 12 hours prior to competing, and is limited to application to the back and dorsal pelvis areas. No Shockwave Therapy is permitted within the 12 hours prior to competing. This exception is permitted only when the “Trainer” as defined under GR404 properly files, or causes to be properly filed, an Equine Drugs and Medications Report Form with the Steward/Technical Delegate or competition office representative within one hour after the administration of Shockwave Therapy or one hour after the Steward/Technical Delegate or competition office representative returns to duty if the administration occurs at a time outside competition hours. The Steward/Technical Delegate or competition office representative shall sign and record the time of receipt on the Equine Drugs and Medications Report Form.

5. No kinesiotape or self-adhesive patches may be used on any horse while mounted at any time during competition. Kinesiotape and self-adhesive patches are permitted exclusively while the horse is unmounted in the stabling area. Nasal strips are permitted unless prohibited by specific division rules.